{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:10:07Z","timestamp":1789103407017,"version":"build-2803163510"},"reference-count":98,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["DNM 137713"],"award-info":[{"award-number":["DNM 137713"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Tuberculosis (TB) remains a common cause of death globally. A regimen of 12 doses of isoniazid (INH) and rifapentine given once weekly (INH\/RPT\u20103) has recently been recommended by the World Health Organization for the treatment of latent TB infection (LTBI). We aimed to determine whether the INH\/RPT\u20103 regimen had similar or lesser rates of adverse events compared to other LTBI regimens, namely INH for 9\u00a0months, INH for 6\u00a0months, rifampin for 3 to 4\u00a0months, and rifampin plus INH for 3 to 4\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched MEDLINE, Embase, CENTRAL, PubMed, ICTRP,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>, and Canadian Agency for Drugs and Technologies in Health's Gray Matters Light for randomized, postmarketing, and comparative nonrandomized studies of patients with confirmed LTBI that reported the frequency of at least 1 adverse event of relevance for a regimen of interest. The search included studies published until March 2017. The frequencies of adverse events were extracted and are presented descriptively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 23 randomized and 55 nonrandomized studies were included. Although inconsistent event reporting and high heterogeneity limited comparisons, the adverse event profile of INH\/RPT\u20103 appeared generally favorable. Flu\u2010like reactions were reported with an increased frequency and hepatotoxicity with a lower frequency than standard treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While INH\/RPT\u20103 had an overall low frequency of adverse events compared to INH monotherapy, reporting of adverse events for many regimens was limited meaning results should be interpreted cautiously. Future studies of LTBI treatment would benefit from more complete collection and reporting of adverse events and more consistent definitions of hepatotoxicity.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4423","type":"journal-article","created":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T04:33:44Z","timestamp":1521866024000},"page":"557-566","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-7413","authenticated-orcid":false,"given":"Christopher","family":"Pease","sequence":"first","affiliation":[{"name":"Ottawa Hospital Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute Ottawa Canada"},{"name":"Public Health and Preventive Medicine Ottawa University School of Epidemiology Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Yazdi","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candyce","family":"Hamel","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Barbeau","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Skidmore","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo G.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Ottawa Canada"},{"name":"Ottawa Hospital Research Institute Ottawa Canada"},{"name":"Ottawa University Faculty of Medicine Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization.Guidelines on the management of latent tuberculosis infection.2015."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00120908"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a121593"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2377-x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ323"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1019"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.10.012"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_11_11_1","unstructured":"US Department of Health and Human Services.Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health National Cancer Institute;2010."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_11_13_1","first-page":"401","article-title":"Compliance, tolerance and efficacy of a short course of chemoprophylaxis for tuberculosis","volume":"111","author":"Martinez Alfaro E","year":"2015","journal-title":"Med Clin Barc"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku562"},{"issue":"3","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: A randomized clinical trial of a 3\u2010month, 12\u2010dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino M","journal-title":"JAMA Pediatr"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0510"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078345811435973"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0504"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005136"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-478OC"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-10-200811180-00003"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1157\/13102264"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/520983"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1953OC"},{"issue":"3","key":"e_1_2_11_25_1","first-page":"276","article-title":"Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?","volume":"9","author":"Tortajada C","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(04)74140-8"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.6.2112"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0213-005X(03)72943-7"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111090-00009"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/422724"},{"issue":"5","key":"e_1_2_11_31_1","first-page":"161","article-title":"Assessment of two chemopropyhylaxis regimens for tuberculosis in HIV\u2010infected patients","volume":"115","author":"Martinez\u2010Alfaro E","year":"2000","journal-title":"Med Clin Barc"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06532-X"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8479(96)90007-6"},{"issue":"10","key":"e_1_2_11_34_1","first-page":"761","article-title":"Compliance and tolerance of new antituberculotic short\u2010term chemo\u2010prevention regimes in childhood, a pilot study","volume":"48","author":"Magdorf K","year":"1994","journal-title":"Pneumologie"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","unstructured":"AzamH MatthewJ NanavatiS et al.Treatment of latent tuberculosis infection: A comparison of subjects taking isoniazid or rifampin. ATS Journals (conference abstract B57);2012.","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A3321"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3249-6"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01397-2015"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001164"},{"key":"e_1_2_11_39_1","article-title":"Isoniazid\u2010induced hepatotoxicity in children with latent tuberculosis infection","author":"Devrim I","year":"2015","journal-title":"Minerva Pediatr"},{"key":"e_1_2_11_40_1","unstructured":"GrayE.An audit of 100 consecutive patients on preventative therapy for latent tuberculosis infection (LTBI) at a Sydney clinic (2010\u20102014). Conf Sess 2015 Conf Thorac Soc Aust N Z.2015."},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.3.9804117"},{"key":"e_1_2_11_42_1","unstructured":"PouladfarG AdelianR HosseiniS DehganiS&GholamiS. Latent tuberculosis infection in liver transplantation of adults in Iran: Chemoprophylaxis and the effect on survival rate. 8th International Iranian Clinical Microbiology Conference proceedings 2014."},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0286"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv220"},{"issue":"267","key":"e_1_2_11_45_1","article-title":"Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV\u2010infected people in Spain","volume":"10","author":"Diaz A","year":"2010","journal-title":"BMC Infect Dis"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2010.02.038"},{"issue":"28","key":"e_1_2_11_47_1","article-title":"Referrals for positive tuberculin tests in new health care workers and students: A retrospective cohort study","volume":"10","author":"Xu Y","year":"2010","journal-title":"BMC Public Health"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1086\/600394"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.6.1712"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.17.1863"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1086\/505398"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/422645"},{"issue":"3","key":"e_1_2_11_53_1","first-page":"306","article-title":"Completing tuberculosis prophylaxis in jail: Targeting treatment and comparison of rifampin\/pyrazinamide with isoniazid regimens","volume":"8","author":"Lincoln T","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.1.102"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0554"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000266578.45634.4f"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00034007"},{"key":"e_1_2_11_58_1","unstructured":"GoldbergG.An audit of 100 consecutive patients on preventative therapy for latent tuberculosis infection (LTBI) at a Sydney clinic (2010\u20132014). Respirology.2015; Conference proceedings."},{"key":"e_1_2_11_59_1","unstructured":"EmoriC.Treatment of latent tuberculosis in patients with hepatitis c and advanced fibrosis. Hepatology.2014; Conference proceedings."},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11142.x"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0111-5"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/549473"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2013.11.001"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.07.015"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0677"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2011.tb03108.x"},{"issue":"6","key":"e_1_2_11_67_1","first-page":"719","article-title":"Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil","volume":"13","author":"Machado A","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2024"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80387"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.1.116"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1086\/345906"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1086\/323896"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1086\/314037"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014"},{"key":"e_1_2_11_75_1","doi-asserted-by":"crossref","unstructured":"HaciogluA.How correct are the assumptions made for tuberculosis screening algorythms before TNF\u2010alpha antagonists?Arthritis Rheumatol.2014; Conference Proceedings.","DOI":"10.1136\/annrheumdis-2015-eular.6163"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pit089"},{"issue":"1","key":"e_1_2_11_77_1","first-page":"47","article-title":"Follow up results of latent tuberculosis infection in patients treated with anti\u2010TNF\u2010alpha","volume":"10","author":"Mutlu P","year":"2013","journal-title":"Nobel Med"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318257f7c6"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.10.0558"},{"issue":"5","key":"e_1_2_11_80_1","first-page":"78","article-title":"Contact tracing for tuberculosis and treatment for latent infection in a low incidence country","volume":"138","author":"Langenskiold E","year":"2008","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31818c0134"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206260.320"},{"key":"e_1_2_11_83_1","first-page":"226","article-title":"Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore","author":"Chee C","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_11_84_1","unstructured":"HoC.Programmatic experience with the 12 dose isoniazid\/rifapentine in the US: The post\u2010marketing project. Presented at 18th Annu Conf Union\u2010NAR March 1 2014."},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ766"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw082"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004126"},{"issue":"1","key":"e_1_2_11_88_1","first-page":"S564","article-title":"Analysis of local outbreaks of tuberculosis and benefit from treating LTBI among young students in Guangzhou","author":"Huang H","year":"2017","journal-title":"Hepatol Int"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001329"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154825"},{"issue":"2","key":"e_1_2_11_91_1","first-page":"151","article-title":"Isoniazid hepatitis among pregnant and postpartum Hispanic patients","volume":"104","author":"Franks AL","year":"1989","journal-title":"Public Health Rep"},{"key":"e_1_2_11_92_1","unstructured":"Evaluating the safety of immediate versus deferred isoniazid preventive therapy among HIV\u2010infected pregnant women [Internet]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01494038"},{"key":"e_1_2_11_93_1","unstructured":"Evaluating the pharmacokinetics tolerability and safety of once\u2010weekly rifapentine and isoniazid in HIV\u20101\u2010infected and HIV\u20101\u2010uninfected pregnant and postpartum women with latent tuberculosis infection [Internet]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02651259"},{"issue":"32","key":"e_1_2_11_94_1","article-title":"Systematic reviews of adverse effects: Framework for a structured approach","volume":"7","author":"Loke Y","year":"2007","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"e_1_2_11_95_1","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies","volume":"119","author":"Comstock GW","year":"1979","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"e_1_2_11_96_1","first-page":"773","article-title":"Isoniazid prophylaxis in Alaskan boarding schools. A comparison of two doses","volume":"100","author":"Comstock GW","year":"1969","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"e_1_2_11_97_1","first-page":"935","article-title":"A controlled trial of community\u2010wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock GW","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214289"},{"issue":"4","key":"e_1_2_11_99_1","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow\u2010up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee On Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:36:13Z","timestamp":1751499373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/pds.4423"],"URL":"https:\/\/doi.org\/10.1002\/pds.4423","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"2017-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}